Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma (RPRX) reported strong financial results for Q4 2020, with net cash from operating activities rising 18% to $566 million. Adjusted Cash Receipts grew 9% to $484 million, driven by key assets like the cystic fibrosis franchise and Imbruvica. The company executed $2.4 billion in acquisitions, enhancing its diverse portfolio. For 2021, RPRX expects Adjusted Cash Receipts between $1,910 million and $1,960 million, reflecting a robust outlook with a projected CAGR of 7%-10% from 2020-2025. The firm also maintains a leading market share in biopharma royalty funding.
Royalty Pharma plc (Nasdaq: RPRX) will announce its fourth quarter 2020 financial results on February 17, 2021, prior to U.S. market opening. A conference call will follow at 8:00 a.m. Eastern Time, accessible via phone or a live webcast on the company's Investors page. Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties, maintaining a diverse portfolio that includes royalties from over 45 leading therapies, such as Imbruvica and Xtandi. The company focuses on funding innovation in the biopharmaceutical sector, facilitating late-stage clinical trials and new product launches.
Royalty Pharma (RPRX) has announced its acquisition of Minerva Neurosciences' royalty interest in seltorexant, an antidepressant, for an upfront payment of $60 million and up to $95 million in milestone payments. Seltorexant, currently in Phase 3 for treating major depressive disorder with insomnia, is developed by Janssen Pharmaceutica. The deal is expected to enhance Royalty Pharma's portfolio, while Minerva aims to use proceeds for the development of its lead compound, roluperidone, targeting negative schizophrenia symptoms.
Royalty Pharma (RPRX) has declared a $0.17 dividend per class A share for Q1 2021, marking a 13% increase over the previous quarter. This reflects the company's commitment to returning value to shareholders. The dividend will be paid on March 15, 2021, to shareholders on record as of February 19, 2021. As the largest buyer of biopharmaceutical royalties, Royalty Pharma continues to fund innovation in the sector, collaborating with various biotech and pharmaceutical companies.
Royalty Pharma (Nasdaq: RPRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 10:50 a.m. EST. The presentation is open to investors, analysts, and the public, with a live webcast available at Royalty Pharma Events. A replay will be archived for at least 30 days. Founded in 1996, Royalty Pharma is a leading buyer of biopharmaceutical royalties and funds innovation across the industry, with a portfolio of royalties on over 45 commercial products.
Royalty Pharma plc (Nasdaq: RPRX) announced charitable donations of $7,660,000 to support COVID-19 research at prestigious institutions, including The Rockefeller University and Mount Sinai Health System. This contribution comprises $4,880,000 from Royalty Pharma and $2,880,000 from Pablo and Almudena Legorreta. The funding aims to advance antibody therapy research and studies on seroprevalence and vaccine responses, particularly for minority communities. The initiative underscores Royalty Pharma's commitment to combating the COVID-19 pandemic through scientific innovation.
Royalty Pharma plc (Nasdaq: RPRX) expands its leadership team, promoting Jim Reddoch to Chief Scientific Officer and Marshall Urist to Executive Vice President, Co-Head of Research & Investments. Sandy Balkin joins as Senior Vice President, Strategy and Analytics. This strategic restructuring aims to enhance the company's capabilities in evaluating and executing new investment opportunities. The leadership change reflects a commitment to leveraging data analytics for innovation in the biopharmaceutical sector, amidst growing transaction activities.
Royalty Pharma (RPRX) and Athyrium Capital Management have announced a transaction involving $325 million in funding for BioCryst Pharmaceuticals (BCRX). This includes an upfront payment of $125 million from Royalty Pharma to support the launch of ORLADEYO™ in hereditary angioedema and the development of BCX9930, an oral Factor D inhibitor. BioCryst will also receive a $200 million credit facility from Athyrium, ensuring financial liquidity while aiming for growth in disease treatment areas. This strategic partnership is anticipated to enhance BioCryst's market position significantly.
Royalty Pharma reported strong Q3 2020 results with a 17% increase in net cash from operations, totaling $509 million. Adjusted Cash Receipts rose 12% to $472 million, driven by the CF franchise and Imbruvica. The company announced $2.3 billion in new acquisitions this year and adjusted full-year guidance to $1,780-$1,800 million. Significant investments include a $575 million acquisition of CF royalties. The balance sheet improved with a $6 billion bond offering, extending debt maturity to 12.5 years. Positive clinical data for Trodelvy was also highlighted.
Royalty Pharma (RPRX) has agreed to acquire the residual royalty interest in Vertex Pharmaceuticals' cystic fibrosis treatments from the Cystic Fibrosis Foundation for $575 million, with a potential additional $75 million in milestone payments. This transaction allows Royalty Pharma to retain all royalties above the previous $5.8 billion revenue threshold. The Vertex CF franchise generated over $4.0 billion in net revenues in 2019. This acquisition is expected to bolster Royalty Pharma's Adjusted Cash Receipts and Cash Flow growth, reflecting their commitment to funding biopharmaceutical innovation.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
